Skip to main content
    Z

    Zai Lab Ltd (ZLAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $23.53
    +0.06 (+0.26%)

    Market Cap: $3.07B

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Zai Lab Ltd (ZLAB) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Zai Lab (ZLAB) has a market cap of $3.07B and an enterprise value of $2.77B. It kept -44.91% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 9.68% below the market cap, as cash exceeds debt.

    Market Cap$3.07B
    Enterprise Value$2.77B
    Latest price (Nov 17, 2026)$23.53

    Key Dates

    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.58% in the quarter ended Sep 30, 2026 and shrank 66.07% a year over 2 years.

    Shares Outstanding112.34M
    Shares Change (YoY)+1.94%
    Shares Change (QoQ)+0.58%
    Share Count Growth (2Y CAGR)-66.07%

    Valuation Ratios

    Sales and book value multiples are 6.0x and 4.7x. Its year-end P/S ranged from 4.2x to 407.9x from 2021 to 2025.

    P/S Ratio6.0x
    Forward P/S7.0x
    P/B Ratio4.7x
    P/TBV Ratio5.5x

    Valuation history and multiples

    Price Statistics

    The stock is up 8.18% over 52 weeks and trades 4.04% below its 50-day average.

    Beta (1Y)1.01
    52-Week Change+8.18%
    1-Month Change-2.20%
    3-Month Change-11.94%
    6-Month Change+28.09%
    5-Year Change-78.86%
    Total Return (1Y)+8.18%
    Total Return (3Y CAGR)-5.14%
    Total Return (5Y CAGR)-22.85%
    Return vs SPY (1Y)+3.33%
    Max Drawdown (1Y)-34.73%
    Max Drawdown (3Y)-62.12%
    Sharpe Ratio (1Y)0.27
    Correlation with SPY (1Y)0.27
    50-Day Average$24.52
    200-Day Average$21.37
    52-Week Range$15.96 to $29.02
    RSI (14 Days)46.3
    Average Volume (20 Days)1.33M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.04x current liabilities, and total debt is 0.45x shareholder equity.

    Current Ratio2.04x
    Quick Ratio1.84x
    Debt / Equity0.45x
    Interest Coverage-31.91x

    Returns and Efficiency

    Return on invested capital is -23.58% over the last 12 months, against a 5-year average of -34.41%.

    Return on Equity (ROE)-35.22%
    Return on Assets (ROA)-19.38%
    Return on Invested Capital (ROIC)-23.58%
    Return on Capital Employed (ROCE)-32.79%
    ROE (5Y Average)-38.12%
    ROA (5Y Average)-29.81%
    ROIC (5Y Average)-34.41%
    Asset Turnover0.40x
    Inventory Turnover2.27x
    Receivables Turnover5.95x
    Cash Conversion Cycle-12 days

    Scores

    ZLAB has an Altman Z-Score of -0.04, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-0.04
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $441.73M over the last 12 months is up 0.02% from the 12 months before.

    Revenue$441.73M
    Revenue Growth (YoY)+0.02%
    Gross Profit$241.59M
    Operating Income-$278.15M
    Pretax Income-$202.77M
    Net Income-$198.39M
    EBITDA-$184.57M
    EBIT-$196.60M
    Reported EPS (TTM)-$1.79

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 55.22% of the $1.02B in total assets.

    Cash and Equivalents$549.66M
    Total Debt$252.37M
    Net Cash$297.29M
    Working Capital$440.15M
    Shareholder Equity$563.28M
    Tangible Book Value$477.98M
    Total Assets$1.02B
    Total Liabilities$460.62M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $26.00M of capital spending, operating cash flow left -$185.20M of free cash flow.

    Operating Cash Flow-$159.21M
    Capital Expenditures$26.00M
    Free Cash Flow-$185.20M
    FCF Per Share-$1.48
    Depreciation and Amortization$17.85M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -62.97%.

    Gross Margin54.69%
    Operating Margin-62.97%
    Pretax Margin-45.90%
    Net Margin-44.91%
    EBITDA Margin-41.78%
    EBIT Margin-44.51%
    FCF Margin-41.93%
    Gross Margin (5Y Average)62.97%

    Growth

    Revenue grew 28.86% a year over 3 years.

    Revenue Growth (3Y CAGR)+28.86%
    Revenue Growth (5Y CAGR)+56.54%

    Revenue and profit by year

    Dividends and Yields

    ZLAB does not pay a dividend. Its free cash flow yield is -7.01%.

    FCF Yield-7.01%
    Shareholder Yield0.00%

    Peer Position

    Against 11 similar companies, ZLAB has the 8th highest P/S.

    P/S Ratio6.0x vs 13.1x median
    ROIC-23.58% vs -28.99% median
    Revenue Growth (Trailing 4 Quarters, YoY)+0.02% vs +29.42% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 21.63% a year over the next 5 fiscal years.

    Revenue Growth Forecast (5Y CAGR)+21.63%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ZLAB

    What is ZLAB's market cap?

    Zai Lab has a market cap of $3.07B. Its enterprise value, which adds debt and subtracts cash, is $2.77B.

    How many shares of ZLAB are outstanding?

    Zai Lab has 112.34M shares outstanding. The count is up 1.94% from a year earlier.

    Does ZLAB pay a dividend?

    No. Zai Lab does not pay a dividend.

    How much debt does ZLAB have?

    Zai Lab has $252.37M of total debt and $549.66M of cash and equivalents, a net cash position of $297.29M.